BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Cephalon, ChemGenex Pharmaceuticals deal

Cephalon will acquire the 72.4% of cancer company ChemGenex it does not already own for about A$159 million ($163 million) in cash. The deal, which comprises A$0.70 per share and A$0.02 per option, values ChemGenex at about A$225 million ($231.8 million). The price is a 59% premium...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >